Axsome Therapeutics Inc (AXSM): Great new Director, she really must like...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	129
Posts	2150
Boards Moderated	1
Alias Born	12/27/2007

BioSpecialist

Re: None

Monday, 06/19/2017 9:13:25 AM

Monday, June 19, 2017 9:13:25 AM

Great new Director, she really must like what she sees at Axsome ...

Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors
https://finance.yahoo.com/news/axsome-therapeutics-appoints-myrtle-potter-110000754.html

Ms. Potter was President, Commercial Operations and Chief Operating Officer of Genentech from 2000 to 2005, where she also served on the Executive Committee and was Co-Chair of the Product Portfolio Committee. At Genentech Ms. Potter led the commercialization of a number of products including Avastin™, Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™, and TNkase™. Prior to joining Genentech, Ms. Potter was President of Bristol-Myers Squibb’s $3.5 billion, 3,500-person U.S. Cardiovascular and Metabolic Business. Before Bristol-Myers Squibb, Ms. Potter worked at Merck & Co. for fourteen years in roles of increasing responsibility, including Vice President of an $800 million U.S. pharmaceutical business unit. While at Merck, she started the joint venture entity Astra Merck, which through merger, later became AstraZeneca. She began her career with Procter and Gamble Patient Care Products.

About Myrtle Potter
http://myrtlepotterconsulting.com/myrtle-potter-and-company/myrtle-potter/